GlassScriptPhysician profile
Nathan R Walker
NPI 1629087325
$954.61
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $64.15 · 2021: $83.27 · 2022: $142 · 2023: $27.86 · 2024: $20.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $158.71 | 2019 | |
| Astellas Pharma US INC | $115.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.35 | 2019 | |
| Pfizer INC. | $110.43 | 2019 | |
| Abbott Laboratories | $94.11 | 2020-2022 | |
| Novo Nordisk INC | $92.63 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $64.86 | 2022-2024 | Livalo |
| Abbvie INC. | $45.93 | 2021 | |
| Glaxosmithkline, LLC. | $45.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.84 | 2019 | |
| Amgen INC. | $16.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.